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Abstract 
Purpose of review: In the absence of “hard” clinical-trial evidence to define optimal 
blood pressure (BP) targets and validate different BP measurement techniques, 
management of hypertension in hemodialysis is based on expert opinions. In this 
review, we provide a comparative evaluation of out-of-dialysis BP monitoring versus 
dialysis-unit BP recordings in diagnosing hypertension, guiding its management and 
prognosticating mortality risk. 
Recent findings: Owing to their high variability and poor reproducibility, pre- and 
postdialysis BP recordings provide inaccurate reflection of the actual BP load outside 
of dialysis. Contrary to the reverse association of peridialytic BP with mortality, 
elevated home and ambulatory BP provides a direct mortality signal. Out-of-dialysis 
BP monitoring, even when done in the clinic, is a reliable approach to manage 
hypertension in the dialysis unit. When none of these measures are available, median 
intradialytic systolic BP can provide a better estimate of interdialytic BP levels 
compared to peridialytic BP measurements. 
Summary: Although out-of-dialysis BP monitoring have better diagnostic accuracy 
and prognostic validity, randomized trials are needed to ascertain BP targets for 
managing hypertension in hemodialysis patients. 
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Introduction 
People with end-stage-renal-disease (ESRD) on hemodialysis have one of the 
highest rates of cardiovascular morbidity and mortality [1]. Although elevated blood 
pressure (BP) is a well-established cardiovascular risk factor in the general population 
[2,3], the contribution of hypertension to cardiovascular and all-cause mortality 
among patients on hemodialysis is antithetical; observational studies show an inverse 
relationship of pre- and postdialysis BP with mortality [4]. In sharp contrast, elevated 
BP recorded outside of dialysis is directly related to mortality [5-7].  Furthermore, at 
odds with observational studies, deliberate BP-lowering with antihypertensive 
medications improves clinical outcomes [8,9]. Till date, no trial has randomized 
patients to two different BP targets in dialysis, therefore optimal BP thresholds remain 
unknown [10].  
More than a decade ago, the National Kidney Foundation’s Kidney Disease 
Outcomes Quality Initiative (KDOQI) guidelines based the management of 
hypertension in hemodialysis on an arbitrarily chosen BP standard <140/90 mmHg for 
predialysis BP and <130/80 for postdialysis BP [11]. These recommendations were 
based either on weak evidence or on expert opinion. Since the publication of those 
guidelines, a growing body of evidence suggests that out-of-dialysis BP recordings 
are superior to pre- and postdialysis BP in diagnosing hypertension [12,13], detecting 
evidence of target-organ damage [14], prognosticating the risk for future 
cardiovascular events and mortality [5-7] and guiding the overall management of 
hypertension in hemodialysis [15,16]. 
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In this article, we review the currently available evidence from observational 
and randomized studies aiming to provide a comparative evaluation of out-of-dialysis 
BP monitoring versus dialysis-unit BP recordings with respect to their diagnostic 
accuracy and prognostic validity in hemodialysis. We conclude with a call for 
properly-designed randomized trials comparing different home BP targets in relation 
to clinical outcomes and mortality in order to obtain the highest level of scientific 
evidence in this important area. 
 
Out-of-dialysis BP versus dialysis-unit BP recordings in the management of 
hypertension in hemodialysis  
Dialysis-unit BP recordings 
Management of hypertension among patients on hemodialysis is currently 
based on conventional peridialytic BP recordings [11]. Peridialytic recordings are not 
adequate for diagnosing, managing or assessing the prognosis of hypertension among 
hemodialysis patient for 3 main reasons.  
(i) Poor precision 
Compared with the “gold-standard” method of interdialytic ambulatory BP 
monitoring (ABPM) peridialytic BP recordings are imprecise [13]. The precision of 
peridialytic BP recordings remains poor even if BP measurements are obtained using 
a standardized technique [17].  The precision is likewise poor even if many readings 
are averaged such as over 6 consecutive dialysis sessions over 2 weeks [18]. This 
suggests that the poor measurement technique or the truly high variability of BP from 
one dialysis session to the next can only partially explain the poor agreement between 
peridialytic and interdialytic ambulatory BP [19].  
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(ii) Peridialysis BP and intradialytic hypotension 
Surveys of peridialysis unit BP recordings indicate that associate that among 
patients who achieve currently recommended predialysis BP targets have a higher risk 
for intradialytic hypotension [20]. Intradialytic hypotension is a serious and 
potentially life-threatening dialysis-related complication [21,22].  
(iii) Poor relationship with target organ damage and mortality 
Another factor that raises concerns regarding the external validity of 
peridialytic BP recordings is their poor correlation with indices of target-organ 
damage [14,23,24] as well as their inverse relationship with mortality that contrasts 
the direct and linear prognostic association of home and ambulatory BP recordings [5-
7], as discussed in detail below. 
 
Out-of-dialysis BP monitoring 
Home BP monitoring (HBPM) is widely applied and strongly recommended 
by international guidelines for the diagnosis and management of hypertension in the 
general population [25]. More than any other patient population, the technique of 
HBPM may be particularly valuable among those on hemodialysis for several reasons. 
Contrary to the poor agreement between peridialytic BP and interdialytic ambulatory 
BP, an average self-measured home  systolic BP (SBP) ≥150 mmHg had both 
sensitivity and specificity >80% in detecting interdialytic hypertension, using 44-hour 
ABPM as the reference standard [18]. Contrary to the high short-term variability of 
pre- and postdialysis BP recordings [19], home BP is more reproducible from one 
week to the next [26]. Home BP can also reliably track the changes in 44-hour 
ambulatory BP induced after 4 and 8 weeks of dry-weight reduction, whereas these 
BP responses were less reliably detected when peridialytic BP was used as indicator 
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[26]. Home BP is also superior to peridialytic BP in detecting the presence of target-
organ damage (i.e., echocardiographic left ventricular hypertrophy) [14] and 
predicting the risk for future cardiovascular events and mortality [5,6].  
In addition to the above, HBPM emerges as a simple and reliable approach to 
guide the management of hypertension in hemodialysis as shown in 4 studies. In the 
first study, 41 drug-treated hypertensive hemodialysis patients underwent 
discontinuation of their BP-lowering medications while home BP was being 
monitored on a weekly basis [27]. After the full withdrawal of antihypertensive 
medications over a 3-week wash-out period, 80% of study participants became 
hypertensive, but the other 20% had sustained normotension, suggesting that HBPM 
is a useful tool to assess the appropriateness of antihypertensive therapy [27]. A 
second study, a randomized trial , assigned 65 hemodialysis patients to either home 
BP‑guided or predialysis BP‑guided management of hypertension over a 6-month-
long follow-up [28]. Compared with the predialysis BP-guided group, a significantly 
greater reduction of 9/7 mmHg in 24-hour ambulatory BP was noted among patients 
assigned to home BP-guided management of hypertension [28]. Between-group 
differences in the change of left ventricular mass index were not evident at 6 months. 
This is not surprising given the small size and short duration of the study.  A third 
study, another randomized trial, assigned 34 hemodialysis patients to home BP-guided 
management of hypertension or to standard care. Using HBPM in decision making 
was associated with a significantly higher reduction in weekly averaged predialysis 
BP [29]. The value of home BP monitoring was evaluated in the Hypertension in 
Hemodialysis treated with Atenolol or Lisinopril (HDPAL) trial [30]. HDPAL 
participants measured their BP twice daily (on waking-up and before going to bed) at 
home for 4 days after the mid-week dialysis session and HBPM was repeated on a 
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monthly basis over the 12-month-long course of the trial [30]. HBPM was sufficient 
to guide the management of hypertension in the research setting. HBPM may be 
similarly useful to guide hypertension management in the clinical setting, if this 
method is widely applied in hemodialysis as a simple approach to improve decision 
making.   
Interdialytic ABPM is considered the “gold-standard” technique of BP 
measurement among patients on hemodialysis [31]. Interdialytic ambulatory BP 
readings are valid [32], highly reproducible [33], display strong associations with 
electrocardiographic evidence of left ventricular hypertrophy [14] and  share a direct 
relationship with all-cause mortality [5,6]. The strong prognostic significance of 
interdialytic ambulatory BP is not relied only on the higher number of measurements 
obtained during a 44-hour ABPM, because interdialytic BP is shown to retain its 
strong prognostic association with mortality, even if a small number of randomly 
selected measurements are analyzed [34]. The superiority of out-of-dialysis BP (both 
home and ambulatory) over dialysis-unit BP is more likely explained by the fact that 
measurements sampled over a broader spectrum of situations and activities may 
provide a more precise reflection of the patient’s typical BP burden over time [35,36]. 
In addition, whereas dialysis-unit BP is unavoidably influenced by the white-coat 
effect (i.e. high BP only in-dialysis and normal BP outside of dialysis), the white-coat 
effect is mitigated with self-measured home BP readings and eliminated with the use 
of interdialytic ABPM [25]. Dialysis-unit BP recordings are unable to detect masked 
hypertension (i.e., high BP outside of dialysis and normal BP within dialysis), while 
masked hypertension is easily detectable with HBPM or ABPM [25]; the latter may 
also explain, at least in part, their strong prognostic value, since masked hypertension 
is shown to affect up to 15% of hemodialysis patients and is associated with higher 
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mortality risk in comparison with sustained (intra- and interdialytic) normotension 
[37].  
Although interdialytic ABPM provides intense BP sampling in the short time-
frame (such as 24 or 48 hours), the feasibility to use this technique repeatedly in order 
to guide the management of hypertension over several weeks, months or years is low 
[38]. This has been for long the main reason why BP targets and the overall 
management of hypertension have been based on the readily available pre- and 
postdialysis BP recordings. Instead of basing our therapeutic decisions on this 
unreliable approach, we use HBPM as a simple tool to guide hypertension 
management in the long-term. 
 
Median intradialytic BP as a proxy of interdialytic ambulatory BP 
Agarwal et al. have shown that all the BP readings taken during the dialysis 
procedure including pre- and postdialysis BP measurements provides a more accurate 
reflection of mean interdialytic ambulatory BP [39]. Since both mean and median are 
measures of central tendency and because the calculation of an average is time 
consuming and often impractical to use at the bedside, an alternative approach to 
detect hypertension is the use of the median of the BP readings taken during a single 
dialysis session. Using 44-hour ABPM as the reference method, a mid-week median 
intradialytic BP ≥140/90 mmHg provides approximately 80% sensitivity and 
specificity in diagnosing interdialytic hypertension [39]. Moreover, median 
intradialytic BP is responsive to dry-weight probing and can reliably track the changes 
in interdialytic ambulatory BP evoked by dry-weight reduction [40]. Although the use 
of intradialytic BP may improve the diagnostic accuracy of dialysis-unit BP 
recordings, this approach can be used when neither home nor ambulatory BP is 
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available to diagnose or guide the management of hypertension in hemodialysis 
patients. 
 “Reverse” epidemiology of hypertension in hemodialysis and its association with 
peridialytic BP 
Unlike the direct association of BP with mortality in the general population, 
numerous observational studies have shown that among incident or prevalent 
hemodialysis patients, the relationship between pre- or postdialysis BP recordings 
with mortality is antithetical [4,41]. Indeed, lower predialysis BP is associated with 
higher mortality [42-45], whereas higher pre- and postdialysis BP is either not 
associated or minimally associated with excess mortality [42-45]. This U-shaped 
pattern has been described as “reverse epidemiology” of hypertension, raising 
substantial concerns and uncertainties on whether BP should be lowered in the 
hemodialysis population. It is increasingly recognized, however, that the 
prognostication of the mortality risk is substantially variant when BP is recorded 
outside of dialysis [4]. In sharp contrast to the U-shaped association of peridialytic BP 
recordings with mortality, elevated interdialytic BP is directly related to higher 
mortality hazard [5-7,46,47].  
In the first study to support this notion, Amar et al. [7] prospective followed 
57 treated hypertensive hemodialysis patients over a mean follow-up of 34.4±20.4 
months. After adjustment for age, gender and history of pre-existing cardiovascular 
disease, Cox-regression hazard analysis showed that each 10 mmHg higher 24-hour 
pulse pressure (PP) was associated with 85% increased risk of cardiovascular 
mortality [Relative Risk (RR): 1.85; 95% Confidence Interval (CI): 1.28-2.65] [7]. In 
another cohort of 168 non-diabetic hemodialysis patients without overt cardiovascular 
disease, Tripepi et al. [47] reported that the elevated ratio of the average SBP during 
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night-time and day-time periods (an indicator of the nocturnal BP dipping) was 
associated with 2.52 times higher risk for all-cause mortality [Hazard Ratio (HR): 
2.52; 95% CI: 1.03–6.15) and 4.33 times higher risk for cardiovascular mortality (HR: 
4.33; 95% CI: 0.96–19.61) over a mean follow-up of 3.2 years [47]. 
The relative importance of out-of-dialysis versus dialysis-unit BP recordings 
as predictors of mortality was evaluated in 2 subsequent cohorts of prevalent 
hemodialysis patients. The first study incorporated data from 150 hemodialysis 
patients who had their BP assessed with the use of HBPM for 1 week, ABPM over an 
entire interdialytic interval as well as with routine pre- and postdialysis BP 
measurements over 6 consecutive dialysis treatments [6]. Over a median follow-up of 
24 months, each 1-standard deviation (SD) higher home SBP increased the risk of all-
cause mortality by 35% (HR: 1.35; 95% CI: 0.99-1.84) and each 1-SD higher 44-hour 
ambulatory SBP increased the risk of all-cause death by 46% (HR: 1.46; 95% CI: 
1.09-1.94). In contrast, peridialytic BP recordings had no prognostic association with 
mortality [6]. In a larger cohort of 326 prevalent hemodialysis patients, Agarwal et al. 
[5] showed that over a mean follow-up of 32 months, increasing quartiles of self-
measured home SBP and 44-hour ambulatory SBP were both associated with 
increased mortality (adjusted HRs for increasing quartiles of home SBP: 2.15, 1.7, 
1.44; and for 44-hour ambulatory SBP: 2.51, 3.43, 2.62) [5]. Once again, no such 
relationship was detectable using pre- and postdialysis BP [5]. 
In an observational analysis of Chronic Renal Insufficiency Cohort (CRIC) 
participants with advanced chronic kidney disease (CKD) [46],  the relationship of BP 
with mortality was assessed in 3 different time-periods and clinical settings: (i) when 
participants had an estimated-glomerular-filtration-rate (eGFR) <30 ml/min/1.73m2 
(n=1,708); (ii) when participants initiated hemodialysis and dialysis-unit BP was 
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available (n=403); (iii) when participants had an out-of-dialysis BP measurement in 
the office setting during a prespecified CRIC follow-up visit (n=326). No association 
between SBP and mortality was detectable among participants not yet on 
hemodialysis. A typical U-shaped association between dialysis-unit SBP and 
mortality was evident among incident hemodialysis patients. In contrast, out-of-
dialysis SBP exhibited a direct and linear association with mortality (HR: 1.26; 95% 
CI: 1.14-1.40 for each 10 mmHg higher SBP) [46]. These data suggest that even if the 
techniques of HBPM and ABPM are not available, a few out-of-dialysis BP 
recordings taken in the office setting in a standardized manner retain a superior 
prognostic association with mortality than that of dialysis-unit BP.  
Although the observational design of these studies does not provide cause-
and-effect associations, hemodialysis patients with self-measured home SBP ranging 
from 125 to 145 mmHg or 44-hour ambulatory SBP ranging from 115 to 125 mmHg 
appear to carry the lowest risk for all-cause and cardiovascular mortality (Figure 1) 
[6]. Whether targeting home and ambulatory BP at these thresholds is translated into a 
survival benefit requires randomized controlled trials (RCTs).  
 
Treating hypertension improves clinical outcomes in hemodialysis patients 
To investigate the potential hazards and benefits of deliberate BP-lowering via 
antihypertensive drug therapy, Heerspink et al. [9] performed a meta-analysis of 8 
RCTs incorporating data from 1,697 patients and 495 cardiovascular events. The 
weighted mean difference in change of BP during follow-up between actively treated 
patients and controls was -4.5 mmHg for SBP and -2.3 mmHg for diastolic BP (DBP). 
This BP-lowering effect was associated with a 29% reduction in the risk of 
cardiovascular morbidity (RR: 0.71; 95% CI: 0.55-0.92) and 20% reduction in the risk 
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of all-cause mortality (RR: 0.80; 95% CI: 0.66-0.96) [9]. In a second meta-analysis of 
5 RCTs that was restricted to hemodialysis patients (n= 1,202), Agarwal et al. [8] 
showed that compared with the control therapy or placebo, active-treatment reduced 
by 31% the risk of future cardiovascular events (HR: 0.69; 95% CI: 0.56-0.84). When 
the analysis was stratified according to the hypertension status of patients 
participating in individual RCTs, it was shown the cardiovascular protection offered 
by antihypertensive therapy was greater among hypertensives (HR: 0.49; 95% CI: 
0.35-0.67) [8].  
It has to be noted that these 2 meta-analyses included RCTs aiming to evaluate 
the effect of different antihypertensive agents on clinical outcomes and not RCTs 
directly comparing different BP targets [8,9]. Accordingly, the causality between BP-
lowering and subsequent improvement in clinical outcomes remains unproven. The 
results of these 2 meta-analyses, however, add to the growing body of observational 
evidence supporting the notion that hypertension among hemodialysis patients is 
harmful and should be appropriately treated.    
 
Perspectives and directions for future research 
In light of a growing body of evidence supporting the superiority of out-of-
dialysis over dialysis-unit BP recordings in detecting hypertension and 
prognosticating the risk of mortality, a high priority goal of future research is the 
assessment of the feasibility and cost-effectiveness of HBPM in the hemodialysis 
population. Ideally, we need RCTs comparing the effect of home BP-guided versus 
dialysis-unit BP guided management of hypertension on interdialytic ambulatory BP, 
regression of target-organ damage and improvement in clinical outcomes and 
mortality. The absence of “hard” clinical-trial evidence to prove that BP-lowering is 
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directly translated into survival benefit is another critical gap in the management of 
hypertension in hemodialysis. The Blood Pressure in Dialysis (BID) is a proof of 
concept study that attempts to target BP to different targets in this population [48]. 
Briefly, BID is a safety and feasibility study and is planning to randomize 120 
hemodialysis patients to either a predialysis SBP target of 110-140 mmHg or 155-165 
mmHg. As feasibility parameters, BID will assess recruitment and withdrawal rates, 
adherence to the prespecified BP measurement methods as well as the adequate 
separation in the achieved BP levels between the 2 study arms [48]. As safety 
endpoints, the BID trial will evaluate the difference between the lower and the higher 
SBP target in the incidence of intradialytic hypotension and other serious adverse 
events. A number of surrogate risk markers, such as the between-group differences in 
change of left ventricular mass index, aortic pulse wave velocity and health-related 
quality of life will be assessed as secondary efficacy endpoints [48]. This trial is a first 
step in the long road towards an optimal management of hypertension in 
hemodialysis. Additional research efforts, mainly RCTs using out-of-dialysis BP 
monitoring and evaluating different home BP targets in relation to clinical outcomes 
and mortality, are needed to fully elucidate this critical issue [49,50]. In the meantime 
and until compelling clinical-trial evidence become available, lowering self-measured 
home BP <140/90 mmHg appears to be a reasonable target for management of 
hypertension in hemodialysis. If home BP is not available, median midweek 
intradialytic BP <140/90 mmHg would appear a reasonable target. 
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KEY POINTS 
• Home and ambulatory BP recordings are superior to conventional BP readings 
obtained shortly before or after dialysis in diagnosing hypertension, assessing 
BP control, detecting evidence of target-organ damage and prognosticating the 
risk for future cardiovascular events and mortality among patients on 
hemodialysis. 
• Home BP-guided management of hypertension culminates in significantly 
higher reduction in interdialytic ambulatory BP versus conventional 
management based on peridialytic BP recordings. 
• The “reverse” epidemiology of hypertension in hemodialysis is debated by 
prospective observational studies showing that elevated home and ambulatory 
BP are directly and linearly associated with excess mortality risk. 
• Meta-analyses of randomized controlled trials showed that deliberate BP-
lowering with antihypertensive medication is associated with improvement in  
clinical outcomes and mortality, providing additional support to the notion that 
hypertension in hemodialysis is harmful and should be controlled. 
• In the absence of “hard” clinical-trial evidence to define optimal BP targets, 
the design of properly-designed RCTs comparing different home BP 
thresholds in relation to clinical outcomes and mortality in a high-priority goal 
of future research in the field of hypertension in hemodialysis.   
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Figure titles and legends 
Figure 1: Prognostic association of dialysis-unit and interdialytic BP with mortality 
among patients on hemodialysis. 
 
Hazard ratios for all-cause mortality for quartiles of systolic BP. Both home BP and 
ambulatory BP were prognostically informative. Conversely, dialysis-unit BP 
recordings did not achieve statistical significance in terms of prognostic value. Home 
systolic BP ranging from 125 to 145 mmHg or 44-hour ambulatory systolic BP 
ranging from 115 to 125 mmHg appear to carry the lowest risk for all-cause mortality. 
(Reprinted with permission from Alborzi et al. Home blood pressures are of greater 
prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 
2:1228–34) 

